首页 > 最新文献

Clinical Journal of Gastroenterology最新文献

英文 中文
Two duodenal sessile serrated lesions in a patient with serrated polyposis syndrome: case report and review of the literature. 锯齿状息肉病综合征患者的两个十二指肠无梗锯齿状病变:病例报告和文献复习。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-11 DOI: 10.1007/s12328-025-02165-4
Hitomi Hori, Yasuaki Kitamura, Saori Matsui, Kyosuke Takahashi, Mayumi Inaba, Akihiko Watanabe

The serrated neoplastic pathway has been reported to be involved in the development of colorectal cancer, and serrated lesions are recognized to have malignant potential. Recently, serrated lesions of the duodenum have been increasingly reported. Serrated polyposis syndrome (SPS) is characterized by multiple serrated lesions in the colon; however, it is unknown whether serrated lesions in the duodenum occur in patients with SPS. A 58-year-old man with SPS underwent a routine colonoscopy. When he underwent esophagogastroduodenoscopy for screening, two 4-mm white flat-elevated lesions in the second portion of the duodenum were found. The biopsy results were suggestive of sessile serrated lesions (SSLs); therefore, we performed endoscopic mucosal resection with a cap-fitted pan-endoscope for therapeutic purposes. Pathology results showed an SSL in the duodenum. One SSL lesion was positive for the BRAF mutation; multiple duodenal SSLs in patients with SPS are rare, and there are no previous reports of BRAF mutation-positive SSLs. The grade and molecular abnormalities of duodenal SSLs are currently unknown, as is the relationship between SPS and duodenal SSL. Further case accumulation is expected.

据报道,锯齿状肿瘤通路与结直肠癌的发展有关,锯齿状病变被认为具有恶性潜能。近年来,十二指肠锯齿状病变的报道越来越多。锯齿状息肉病综合征(SPS)的特征是结肠内有多个锯齿状病变;然而,尚不清楚SPS患者是否会出现十二指肠的锯齿状病变。一位58岁的SPS患者接受了常规结肠镜检查。患者行食管胃十二指肠镜检查时,发现十二指肠第二段有2个4毫米白色平升高灶。活检结果提示为无梗锯齿状病变(sls);因此,为了治疗目的,我们采用了带帽的泛内窥镜进行内镜粘膜切除术。病理结果显示十二指肠有一层SSL。一个SSL病变为BRAF突变阳性;SPS患者多发十二指肠SSLs是罕见的,并且之前没有BRAF突变阳性SSLs的报道。目前尚不清楚十二指肠SSL的级别和分子异常,以及SPS与十二指肠SSL的关系。预计病例还会进一步积累。
{"title":"Two duodenal sessile serrated lesions in a patient with serrated polyposis syndrome: case report and review of the literature.","authors":"Hitomi Hori, Yasuaki Kitamura, Saori Matsui, Kyosuke Takahashi, Mayumi Inaba, Akihiko Watanabe","doi":"10.1007/s12328-025-02165-4","DOIUrl":"10.1007/s12328-025-02165-4","url":null,"abstract":"<p><p>The serrated neoplastic pathway has been reported to be involved in the development of colorectal cancer, and serrated lesions are recognized to have malignant potential. Recently, serrated lesions of the duodenum have been increasingly reported. Serrated polyposis syndrome (SPS) is characterized by multiple serrated lesions in the colon; however, it is unknown whether serrated lesions in the duodenum occur in patients with SPS. A 58-year-old man with SPS underwent a routine colonoscopy. When he underwent esophagogastroduodenoscopy for screening, two 4-mm white flat-elevated lesions in the second portion of the duodenum were found. The biopsy results were suggestive of sessile serrated lesions (SSLs); therefore, we performed endoscopic mucosal resection with a cap-fitted pan-endoscope for therapeutic purposes. Pathology results showed an SSL in the duodenum. One SSL lesion was positive for the BRAF mutation; multiple duodenal SSLs in patients with SPS are rare, and there are no previous reports of BRAF mutation-positive SSLs. The grade and molecular abnormalities of duodenal SSLs are currently unknown, as is the relationship between SPS and duodenal SSL. Further case accumulation is expected.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"786-792"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic closure of 5-cm long esophageal perforation in an elderly patient with achalasia. 内镜下封堵老年贲门失弛缓症患者5厘米长的食管穿孔。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-12 DOI: 10.1007/s12328-025-02182-3
Ippei Tanaka, Haruhiro Inoue, Kei Ushikubo, Kazuki Yamamoto, Yohei Nishikawa, Kaori Owada, Mayo Tanabe, Manabu Onimaru, Koji Otsuka

Chronic esophageal achalasia can lead to significant morphological changes in the esophagus, posing challenges during endoscopic examinations. Here, we report a case of iatrogenic esophageal perforation in an elderly patient with achalasia. An 80-year-old woman presented with severe dysphagia and marked weight loss, indicating chronic malnutrition. She had a 50-year history of achalasia, previously treated with a Heller-Dor operation. Endoscopic evaluation was performed to assess the esophageal condition; however, during the procedure, an iatrogenic perforation occurred. The patient underwent urgent management under general anesthesia. Two drainage tubes were placed at the base of the right thoracic cavity. Saline infusion via the perforation site enabled endoscopic lavage of the thoracic cavity. The perforation was initially closed with the thread-and-clip technique. After 30 days, the perforation site had developed into a fistula approximately 1 cm in size. Attempts to close it using argon plasma coagulation ablation and over-the-scope clip were unsuccessful. It was presumed that the significant accumulation of fluid in the esophagus due to achalasia was hindering fistula closure. Consequently, peroral endoscopic myotomy was performed, ultimately leading to the closure of the fistula. Despite requiring prolonged hospitalization for recovery and nutritional rehabilitation, the patient was eventually discharged in stable condition, able to consume meals without difficulty. This case underscores the high risk of esophageal perforation during endoscopy in elderly patients with advanced achalasia and subsequent malnutrition. Furthermore, it highlights the potential for successful management of severe complications like esophageal perforation through advanced endoscopic techniques, thereby avoiding the need for surgical intervention.

慢性食道失弛缓症可导致食道显著的形态学改变,给内镜检查带来挑战。在此,我们报告一例老年贲门失弛缓症患者的医源性食管穿孔。一位80岁的女性表现为严重的吞咽困难和明显的体重下降,表明慢性营养不良。她有50年的贲门失弛缓症病史,之前接受过Heller-Dor手术。内镜下评估食管状况;然而,在手术过程中,发生了医源性穿孔。病人在全身麻醉下接受紧急治疗。在右侧胸腔底部放置两根引流管。经穿孔部位输注生理盐水,使腔镜对胸腔进行灌洗。最初使用螺纹夹技术关闭射孔。30天后,穿孔部位形成约1厘米大小的瘘管。尝试用氩等离子体凝固消融和过镜夹闭合它是不成功的。据推测,贲门失弛缓症引起的食道内大量积液阻碍了瘘管的关闭。因此,进行了经口内窥镜肌切开术,最终导致瘘关闭。尽管需要长期住院恢复和营养康复,但患者最终出院时情况稳定,能够毫无困难地进食。该病例强调了老年晚期贲门失弛缓症和随后的营养不良患者在内镜检查时食管穿孔的高风险。此外,它强调了通过先进的内窥镜技术成功管理严重并发症(如食管穿孔)的潜力,从而避免了手术干预的需要。
{"title":"Endoscopic closure of 5-cm long esophageal perforation in an elderly patient with achalasia.","authors":"Ippei Tanaka, Haruhiro Inoue, Kei Ushikubo, Kazuki Yamamoto, Yohei Nishikawa, Kaori Owada, Mayo Tanabe, Manabu Onimaru, Koji Otsuka","doi":"10.1007/s12328-025-02182-3","DOIUrl":"10.1007/s12328-025-02182-3","url":null,"abstract":"<p><p>Chronic esophageal achalasia can lead to significant morphological changes in the esophagus, posing challenges during endoscopic examinations. Here, we report a case of iatrogenic esophageal perforation in an elderly patient with achalasia. An 80-year-old woman presented with severe dysphagia and marked weight loss, indicating chronic malnutrition. She had a 50-year history of achalasia, previously treated with a Heller-Dor operation. Endoscopic evaluation was performed to assess the esophageal condition; however, during the procedure, an iatrogenic perforation occurred. The patient underwent urgent management under general anesthesia. Two drainage tubes were placed at the base of the right thoracic cavity. Saline infusion via the perforation site enabled endoscopic lavage of the thoracic cavity. The perforation was initially closed with the thread-and-clip technique. After 30 days, the perforation site had developed into a fistula approximately 1 cm in size. Attempts to close it using argon plasma coagulation ablation and over-the-scope clip were unsuccessful. It was presumed that the significant accumulation of fluid in the esophagus due to achalasia was hindering fistula closure. Consequently, peroral endoscopic myotomy was performed, ultimately leading to the closure of the fistula. Despite requiring prolonged hospitalization for recovery and nutritional rehabilitation, the patient was eventually discharged in stable condition, able to consume meals without difficulty. This case underscores the high risk of esophageal perforation during endoscopy in elderly patients with advanced achalasia and subsequent malnutrition. Furthermore, it highlights the potential for successful management of severe complications like esophageal perforation through advanced endoscopic techniques, thereby avoiding the need for surgical intervention.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"819-824"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency rectal obstruction caused by pancreatic cancer metastasizing to the rectum. 胰腺癌转移至直肠引起的急诊直肠梗阻。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-29 DOI: 10.1007/s12328-025-02194-z
Takuya Shimogawa, Takanobu Yamao, Nobuya Daitoku, Mayumi Nagayasu, Kunitaka Kuramoto

Pancreatic cancer is an aggressive malignancy with a poor prognosis. Although distant metastases are common at the time of diagnosis, metastatic spread to the rectum is rare. Furthermore, there have been no reports of acute rectal obstruction caused by a metastatic rectal tumor from pancreatic cancer. A 75-year-old man presented with lower gastrointestinal bleeding, abdominal pain, and distention. Colonoscopy and abdominal computed tomography confirmed acute rectal obstruction. Additionally, computed tomography identified a tumor in the pancreatic tail. An emergency loop colostomy on the transverse colon was performed. During preoperative assessment, the patient was initially considered to have synchronous primary cancers of the rectum and pancreas. However, microscopic examination confirmed that the rectal tumor was a metastasis from pancreatic cancer. Chemotherapy for pancreatic cancer was initiated immediately, and as of this writing, the patient has survived for more than 1 year. In summary, we herein report a rare case of pancreatic cancer metastasizing to the rectum. The prognosis of pancreatic cancer with distant metastases may be improved by enabling early initiation of chemotherapy. Minimally invasive surgery could be an effective approach for managing rectal obstruction due to metastasis.

胰腺癌是一种侵袭性恶性肿瘤,预后差。虽然在诊断时远处转移是常见的,但转移扩散到直肠是罕见的。此外,还没有由胰腺癌转移性直肠肿瘤引起的急性直肠梗阻的报道。男性,75岁,下消化道出血,腹痛,腹胀。结肠镜检查和腹部计算机断层扫描证实急性直肠梗阻。此外,计算机断层扫描发现胰腺尾部有肿瘤。在横结肠上进行了紧急环形结肠造口术。在术前评估时,患者最初被认为患有同步原发性直肠癌和胰腺癌。然而,显微镜检查证实直肠肿瘤为胰腺癌转移灶。胰腺癌的化疗立即开始,截至撰写本文时,患者已经存活了1年多。总之,我们在此报告一例罕见的胰腺癌转移到直肠的病例。胰腺癌远处转移的预后可以通过早期化疗得到改善。微创手术是治疗直肠转移性梗阻的有效方法。
{"title":"Emergency rectal obstruction caused by pancreatic cancer metastasizing to the rectum.","authors":"Takuya Shimogawa, Takanobu Yamao, Nobuya Daitoku, Mayumi Nagayasu, Kunitaka Kuramoto","doi":"10.1007/s12328-025-02194-z","DOIUrl":"10.1007/s12328-025-02194-z","url":null,"abstract":"<p><p>Pancreatic cancer is an aggressive malignancy with a poor prognosis. Although distant metastases are common at the time of diagnosis, metastatic spread to the rectum is rare. Furthermore, there have been no reports of acute rectal obstruction caused by a metastatic rectal tumor from pancreatic cancer. A 75-year-old man presented with lower gastrointestinal bleeding, abdominal pain, and distention. Colonoscopy and abdominal computed tomography confirmed acute rectal obstruction. Additionally, computed tomography identified a tumor in the pancreatic tail. An emergency loop colostomy on the transverse colon was performed. During preoperative assessment, the patient was initially considered to have synchronous primary cancers of the rectum and pancreas. However, microscopic examination confirmed that the rectal tumor was a metastasis from pancreatic cancer. Chemotherapy for pancreatic cancer was initiated immediately, and as of this writing, the patient has survived for more than 1 year. In summary, we herein report a rare case of pancreatic cancer metastasizing to the rectum. The prognosis of pancreatic cancer with distant metastases may be improved by enabling early initiation of chemotherapy. Minimally invasive surgery could be an effective approach for managing rectal obstruction due to metastasis.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"988-994"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous endoscopic necrosectomy for extensive walled-off necrosis using two endoscopes simultaneously: a report of two cases. 经皮内窥镜切除大面积壁脱性坏死2例报告。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-21 DOI: 10.1007/s12328-025-02179-y
Keigo Oshiro, Kazuo Hara, Tomoki Ogata, Hiroki Koda, Nozomi Okuno, Shin Haba, Takamichi Kuwahara

Endoscopic step-up approach, which involves endoscopic ultrasound-guided drainage followed by necrosectomy, has been suggested as a potentially advantageous alternative to the surgical step-up approach for walled-off necrosis (WON) following acute pancreatitis. Recent studies indicate that although there is no significant difference in major complications or mortality between the two approaches, the endoscopic step-up approach is often preferred due to shorter hospital stays and lower re-intervention rates. However, a multidisciplinary approach should be considered for complex cases. Transgastric or transduodenal approaches can be challenging in cases of extensive intra-abdominal WON, whereas percutaneous endoscopic necrosectomy (PEN) has been reported as a safe and effective minimally invasive technique. We report the cases of two critically ill patients with extensive WON and uncontrolled sepsis who were successfully treated with simultaneous dual-endoscopic PEN. This approach may offer a promising strategy for enhancing treatment efficacy in extensive WON when performed appropriately.

内镜下强化入路,包括内镜下超声引导引流和坏死切除术,已被认为是治疗急性胰腺炎后壁闭塞性坏死(WON)的潜在优势替代手术强化入路。最近的研究表明,虽然两种入路在主要并发症或死亡率方面没有显著差异,但内镜下升级入路往往因住院时间短和再干预率低而成为首选。然而,对于复杂的病例,应考虑多学科方法。经胃或经十二指肠入路对于广泛的腹腔内WON来说是具有挑战性的,而经皮内窥镜下坏死切除术(PEN)已被报道为一种安全有效的微创技术。我们报告了两例重症患者广泛的WON和不受控制的败血症,他们成功地治疗了同时双内镜下的PEN。如果执行得当,这种方法可能为提高广泛WON的治疗效果提供了一种有希望的策略。
{"title":"Percutaneous endoscopic necrosectomy for extensive walled-off necrosis using two endoscopes simultaneously: a report of two cases.","authors":"Keigo Oshiro, Kazuo Hara, Tomoki Ogata, Hiroki Koda, Nozomi Okuno, Shin Haba, Takamichi Kuwahara","doi":"10.1007/s12328-025-02179-y","DOIUrl":"10.1007/s12328-025-02179-y","url":null,"abstract":"<p><p>Endoscopic step-up approach, which involves endoscopic ultrasound-guided drainage followed by necrosectomy, has been suggested as a potentially advantageous alternative to the surgical step-up approach for walled-off necrosis (WON) following acute pancreatitis. Recent studies indicate that although there is no significant difference in major complications or mortality between the two approaches, the endoscopic step-up approach is often preferred due to shorter hospital stays and lower re-intervention rates. However, a multidisciplinary approach should be considered for complex cases. Transgastric or transduodenal approaches can be challenging in cases of extensive intra-abdominal WON, whereas percutaneous endoscopic necrosectomy (PEN) has been reported as a safe and effective minimally invasive technique. We report the cases of two critically ill patients with extensive WON and uncontrolled sepsis who were successfully treated with simultaneous dual-endoscopic PEN. This approach may offer a promising strategy for enhancing treatment efficacy in extensive WON when performed appropriately.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"905-909"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series. 低基线血清IL-6患者联合杜伐单抗治疗肝细胞癌的免疫相关不良事件:一个病例系列
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-09 DOI: 10.1007/s12328-025-02176-1
Tsubasa Nobusawa, Shun Kaneko, Miyako Murakawa, Jun Tsuchiya, Masato Miyoshi, Fukiko Kawai-Kitahata, Mina Nakagawa, Sei Kakinuma, Yasuhiro Asahina, Ryuichi Okamoto

Systemic therapy for advanced hepatocellular carcinoma (HCC) has progressed significantly, yet the management of immune-related adverse events (irAEs) remains a challenge, particularly with anti-CTLA-4 and anti-PD-L1 antibodies. We present two cases of severe irAEs during durvalumab plus tremelimumab (DT) therapy, demonstrating successful management and favorable outcomes. In Case 1, a 76-year-old male with metabolic-associated steatotic liver disease-related HCC experienced disease progression after lenvatinib and subsequently initiated DT therapy. He developed Grade 3 immune-related myositis at week 5, which was successfully managed with prednisolone. A partial response (PR) was achieved and maintained, with a 55% tumor reduction at 8 months. In Case 2, a 73-year-old male with alcoholic cirrhosis and a 16-cm HCC received DT therapy. On day 19, he developed Grade 3 immune-related hepatitis and thyroiditis, which were controlled with prednisolone. After steroid tapering, durvalumab was successfully rechallenged, maintaining a 38% tumor reduction at 6 months with a sustained PR. In the case series, lower baseline serum interleukin (IL)-6 levels were associated with the development of Grade ≥ 3 irAEs. These findings suggest that IL-6 may serve as a predictive biomarker, aiding in risk assessment and the optimization of individualized treatment strategies prior to anti-CTLA-4 therapy.

晚期肝细胞癌(HCC)的全身治疗已经取得了显著进展,但免疫相关不良事件(irAEs)的管理仍然是一个挑战,特别是抗ctla -4和抗pd - l1抗体。我们报告了两例在durvalumab + tremelimumab (DT)治疗期间发生的严重irAEs,显示出成功的管理和良好的结果。在病例1中,一名患有代谢相关脂肪变性肝病相关HCC的76岁男性患者在服用lenvatinib后病情进展,随后开始DT治疗。他在第5周出现了3级免疫相关肌炎,泼尼松龙治疗成功。达到并维持部分缓解(PR), 8个月时肿瘤减少55%。在病例2中,一名73岁男性酒精性肝硬化和16厘米HCC接受DT治疗。第19天,患者出现3级免疫相关性肝炎和甲状腺炎,经强的松龙控制。在类固醇逐渐减量后,杜伐单抗成功地再次挑战,在持续PR的6个月时保持38%的肿瘤减少。在病例系列中,较低的基线血清白细胞介素(IL)-6水平与≥3级irae的发展相关。这些发现表明,IL-6可能作为一种预测性生物标志物,有助于在抗ctla -4治疗之前进行风险评估和个性化治疗策略的优化。
{"title":"Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series.","authors":"Tsubasa Nobusawa, Shun Kaneko, Miyako Murakawa, Jun Tsuchiya, Masato Miyoshi, Fukiko Kawai-Kitahata, Mina Nakagawa, Sei Kakinuma, Yasuhiro Asahina, Ryuichi Okamoto","doi":"10.1007/s12328-025-02176-1","DOIUrl":"10.1007/s12328-025-02176-1","url":null,"abstract":"<p><p>Systemic therapy for advanced hepatocellular carcinoma (HCC) has progressed significantly, yet the management of immune-related adverse events (irAEs) remains a challenge, particularly with anti-CTLA-4 and anti-PD-L1 antibodies. We present two cases of severe irAEs during durvalumab plus tremelimumab (DT) therapy, demonstrating successful management and favorable outcomes. In Case 1, a 76-year-old male with metabolic-associated steatotic liver disease-related HCC experienced disease progression after lenvatinib and subsequently initiated DT therapy. He developed Grade 3 immune-related myositis at week 5, which was successfully managed with prednisolone. A partial response (PR) was achieved and maintained, with a 55% tumor reduction at 8 months. In Case 2, a 73-year-old male with alcoholic cirrhosis and a 16-cm HCC received DT therapy. On day 19, he developed Grade 3 immune-related hepatitis and thyroiditis, which were controlled with prednisolone. After steroid tapering, durvalumab was successfully rechallenged, maintaining a 38% tumor reduction at 6 months with a sustained PR. In the case series, lower baseline serum interleukin (IL)-6 levels were associated with the development of Grade ≥ 3 irAEs. These findings suggest that IL-6 may serve as a predictive biomarker, aiding in risk assessment and the optimization of individualized treatment strategies prior to anti-CTLA-4 therapy.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"899-904"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic lymphocytic leukemia complicated by non-cirrhotic portal hypertension: an autopsy case report. 慢性淋巴细胞白血病合并非肝硬化门静脉高压症1例尸检报告。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-16 DOI: 10.1007/s12328-025-02184-1
Akiri Hiraide, Keisuke Ojiro, Kimihiro Matsumoto, Tadashi Katayama, Kenji Nakamura, Hiroshi Kishikawa, Aya Sasaki, Nobuhiro Nakamoto, Jiro Nishida

Portal hypertension typically occurs in cirrhosis but can rarely develop in the absence of hepatic fibrosis, particularly in hematologic malignancies such as chronic lymphocytic leukemia (CLL). We report a 70-year-old man with CLL who developed portal hypertension, presenting with massive splenomegaly, esophageal variceal rupture, and refractory ascites. He was initially diagnosed with alcohol-related cirrhosis based on a history of alcohol use and elevated liver stiffness on elastography. Chemotherapy had been discontinued due to cerebral hemorrhage and cytopenia. Ascites was refractory to and intolerant of diuretics and was worsened by renal dysfunction due to spontaneous bacterial peritonitis. After resolution of peritonitis, partial splenic artery embolization (PSE) was performed to relieve portal hypertension. Although ascites improved post-PSE, the patient developed a severe infection and died. Autopsy revealed no cirrhosis or hepatic fibrosis; instead, portal hypertension was attributed to CLL cell infiltration leading to splenomegaly and portal venous obstruction. This case underscores the need to consider hematologic malignancies as potential causes of non-cirrhotic portal hypertension. While PSE may offer symptomatic relief, the risk of fatal infection must be carefully weighed in patients with hematological malignancies. Histologic confirmation remains critical for accurate diagnosis in atypical presentations of portal hypertension.

门脉高压通常发生在肝硬化,但在没有肝纤维化的情况下很少发生,特别是在血液恶性肿瘤如慢性淋巴细胞白血病(CLL)中。我们报告一位70岁的慢性淋巴细胞白血病患者,他发展为门脉高压,表现为脾肿大、食管静脉曲张破裂和难治性腹水。根据酒精使用史和弹性成像显示肝脏僵硬度升高,患者最初被诊断为酒精相关性肝硬化。因脑出血和细胞减少而停止化疗。腹水对利尿剂难以耐受,并因自发性细菌性腹膜炎引起肾功能不全而加重。腹膜炎消退后,行部分脾动脉栓塞术(PSE)缓解门静脉高压。虽然pse后腹水有所改善,但患者发生严重感染并死亡。尸检显示无肝硬化或肝纤维化;相反,门静脉高压归因于CLL细胞浸润导致脾肿大和门静脉阻塞。这个病例强调需要考虑血液恶性肿瘤作为非肝硬化门静脉高压症的潜在原因。虽然PSE可以缓解症状,但必须仔细权衡血液恶性肿瘤患者致命感染的风险。组织学确认仍然是准确诊断门静脉高压症的关键。
{"title":"Chronic lymphocytic leukemia complicated by non-cirrhotic portal hypertension: an autopsy case report.","authors":"Akiri Hiraide, Keisuke Ojiro, Kimihiro Matsumoto, Tadashi Katayama, Kenji Nakamura, Hiroshi Kishikawa, Aya Sasaki, Nobuhiro Nakamoto, Jiro Nishida","doi":"10.1007/s12328-025-02184-1","DOIUrl":"10.1007/s12328-025-02184-1","url":null,"abstract":"<p><p>Portal hypertension typically occurs in cirrhosis but can rarely develop in the absence of hepatic fibrosis, particularly in hematologic malignancies such as chronic lymphocytic leukemia (CLL). We report a 70-year-old man with CLL who developed portal hypertension, presenting with massive splenomegaly, esophageal variceal rupture, and refractory ascites. He was initially diagnosed with alcohol-related cirrhosis based on a history of alcohol use and elevated liver stiffness on elastography. Chemotherapy had been discontinued due to cerebral hemorrhage and cytopenia. Ascites was refractory to and intolerant of diuretics and was worsened by renal dysfunction due to spontaneous bacterial peritonitis. After resolution of peritonitis, partial splenic artery embolization (PSE) was performed to relieve portal hypertension. Although ascites improved post-PSE, the patient developed a severe infection and died. Autopsy revealed no cirrhosis or hepatic fibrosis; instead, portal hypertension was attributed to CLL cell infiltration leading to splenomegaly and portal venous obstruction. This case underscores the need to consider hematologic malignancies as potential causes of non-cirrhotic portal hypertension. While PSE may offer symptomatic relief, the risk of fatal infection must be carefully weighed in patients with hematological malignancies. Histologic confirmation remains critical for accurate diagnosis in atypical presentations of portal hypertension.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"925-930"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involving nanoliposomal irinotecan with fluorouracil and folinic acid. 采用纳米脂质体伊立替康联合氟尿嘧啶和亚叶酸化疗的胰腺癌、腹膜细胞学阳性和肝转移患者的成功转化手术。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-04 DOI: 10.1007/s12328-025-02175-2
Ayaka Itoh, Kazuto Shibuya, Nana Kimura, Mina Fukasawa, Shunsuke Kawai, Takamichi Igarashi, Toru Watanabe, Katsuhisa Hirano, Isaku Yoshioka, Tsutomu Fujii

A 67-year-old woman was diagnosed with pancreatic head cancer. Staging laparoscopy (SL) was performed, peritoneal cytology (CY) was positive (CY1), and a peritoneal access port was created. The patient was started on nab-paclitaxel plus gemcitabine therapy (GnP). After 6 courses of GnP therapy, computed tomography revealed a single metastatic tumour in the liver. The disease was considered advanced, and nal-IRI + 5-FU/LV therapy was initiated as second-line treatment. After 13 courses of treatment, both the liver nodule and the primary tumour decreased in size, and CY became negative (CY0). A second-look SL and partial resection of the metastatic liver were performed. Thereafter, after 7 additional courses of nal-IRI + 5-FU/LV therapy. A third-look SL revealed no distant metastasis, and CY0. Then, pancreatoduodenectomy was performed as the conversion surgery. Histological examination revealed Grade 1a disease. She resumed adjuvant chemotherapy and is alive 7 months postoperatively without any signs of recurrence. In our rare case, a patient with CY1 pancreatic cancer and liver metastasis was successfully treated with nal-IRI + 5-FU/LV and was able to undergo radical resection. To our knowledge, this is the first report on conversion surgery with this regimen, which is not considered to have a high response rate.

一名67岁的妇女被诊断出患有胰腺癌。进行分期腹腔镜检查(SL),腹膜细胞学检查(CY)阳性(CY1),并建立腹膜通路。患者开始接受nab-紫杉醇加吉西他滨治疗(GnP)。经过6个疗程的GnP治疗后,计算机断层扫描显示肝脏有一个转移性肿瘤。该疾病被认为是晚期,nal-IRI + 5-FU/LV治疗作为二线治疗开始。治疗13个疗程后,肝结节和原发肿瘤大小均减小,CY变为阴性(CY0)。进行了二次检查SL和部分切除转移性肝脏。之后,再进行7个疗程的nal-IRI + 5-FU/LV治疗。第三次检查未发现远处转移和CY0。然后行胰十二指肠切除术作为转换手术。组织学检查显示1a级病变。她恢复了辅助化疗,术后7个月存活,没有任何复发迹象。在我们罕见的病例中,一位CY1胰腺癌并肝转移的患者成功地接受了nal-IRI + 5-FU/LV治疗,并能够进行根治性切除。据我们所知,这是第一次报道这种方案的转换手术,这种方案被认为没有很高的反应率。
{"title":"Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involving nanoliposomal irinotecan with fluorouracil and folinic acid.","authors":"Ayaka Itoh, Kazuto Shibuya, Nana Kimura, Mina Fukasawa, Shunsuke Kawai, Takamichi Igarashi, Toru Watanabe, Katsuhisa Hirano, Isaku Yoshioka, Tsutomu Fujii","doi":"10.1007/s12328-025-02175-2","DOIUrl":"10.1007/s12328-025-02175-2","url":null,"abstract":"<p><p>A 67-year-old woman was diagnosed with pancreatic head cancer. Staging laparoscopy (SL) was performed, peritoneal cytology (CY) was positive (CY1), and a peritoneal access port was created. The patient was started on nab-paclitaxel plus gemcitabine therapy (GnP). After 6 courses of GnP therapy, computed tomography revealed a single metastatic tumour in the liver. The disease was considered advanced, and nal-IRI + 5-FU/LV therapy was initiated as second-line treatment. After 13 courses of treatment, both the liver nodule and the primary tumour decreased in size, and CY became negative (CY0). A second-look SL and partial resection of the metastatic liver were performed. Thereafter, after 7 additional courses of nal-IRI + 5-FU/LV therapy. A third-look SL revealed no distant metastasis, and CY0. Then, pancreatoduodenectomy was performed as the conversion surgery. Histological examination revealed Grade 1a disease. She resumed adjuvant chemotherapy and is alive 7 months postoperatively without any signs of recurrence. In our rare case, a patient with CY1 pancreatic cancer and liver metastasis was successfully treated with nal-IRI + 5-FU/LV and was able to undergo radical resection. To our knowledge, this is the first report on conversion surgery with this regimen, which is not considered to have a high response rate.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"893-898"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histopathological changes in two patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease treated with pemafibrate: a serial liver biopsy study. 两例高甘油三酯血症和代谢功能障碍相关脂肪变性肝病患者的组织病理学改变:一项系列肝活检研究
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-18 DOI: 10.1007/s12328-025-02185-0
Naruyasu Kakita, Midori Jono, Hiroshi Tsumuro, Shin Satake, Syuko Iwatani, Kenji Aoi, Kazuhiro Katayama

This study investigated histological liver-tissue changes before and after 1 year of pemafibrate treatment in two women with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia who were refractory to ≥ 6 months of lifestyle intervention. The patients underwent paired liver biopsies before and after receiving pemafibrate (0.2 mg, once daily) for 52 weeks. Improvements in the non-alcoholic fatty liver disease activity score and fibrosis stage were examined. In Case 1, pre-treatment liver biopsy revealed 90% steatosis, ballooning, lobular inflammation, and fibrosis (Brunt grade 2, stage 3). Post-treatment, steatosis decreased to 50%, ballooning and inflammation resolved, and fibrosis improved (grade 1, stage 2). In Case 2, pre-treatment liver biopsy showed 70% steatosis, mild lobular inflammation, and fibrosis (grade, 1, stage 3). Post-treatment, steatosis increased to 90%, inflammation resolved, and fibrosis improved (grade 1, stage 1). The fibrosis-4 index improved in both cases; however, shear wave elastography showed no improvement. Pemafibrate may exert antifibrotic and anti-inflammatory effects in MASLD regardless of steatosis trends and that histological assessment remains crucial, especially when non-invasive markers provide inconsistent results. This is the first report to confirm histopathological improvement with pemafibrate via serial liver biopsy, offering important insights into its therapeutic potential for MASLD with dyslipidemia.

本研究调查了两名代谢功能障碍相关脂肪变性肝病(MASLD)和高甘油三酯血症的妇女,她们对≥6个月的生活方式干预难治性,在接受帕玛菲特治疗1年前后肝脏组织的组织学变化。患者在接受pembrofiate (0.2 mg,每日1次)治疗52周前后分别接受配对肝活检。检查非酒精性脂肪肝活动评分和纤维化分期的改善。在病例1中,治疗前肝活检显示90%脂肪变性、球囊化、小叶炎症和纤维化(布伦特2级,3期)。治疗后,脂肪变性降低至50%,水肿和炎症消退,纤维化改善(1级,2期)。病例2,治疗前肝活检显示70%脂肪变性,轻度小叶炎症和纤维化(1级,3期)。治疗后,脂肪变性增加到90%,炎症消退,纤维化改善(1级,1期)。两例患者的纤维化-4指数均有所改善;而横波弹性图没有改善。pemafbrate可能在MASLD中发挥抗纤维化和抗炎作用,无论脂肪变性趋势如何,组织学评估仍然至关重要,特别是当非侵入性标志物提供不一致的结果时。这是首个通过连续肝活检证实pemafitate可改善组织病理学的报告,为其治疗伴有血脂异常的MASLD提供了重要的见解。
{"title":"Histopathological changes in two patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease treated with pemafibrate: a serial liver biopsy study.","authors":"Naruyasu Kakita, Midori Jono, Hiroshi Tsumuro, Shin Satake, Syuko Iwatani, Kenji Aoi, Kazuhiro Katayama","doi":"10.1007/s12328-025-02185-0","DOIUrl":"10.1007/s12328-025-02185-0","url":null,"abstract":"<p><p>This study investigated histological liver-tissue changes before and after 1 year of pemafibrate treatment in two women with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia who were refractory to ≥ 6 months of lifestyle intervention. The patients underwent paired liver biopsies before and after receiving pemafibrate (0.2 mg, once daily) for 52 weeks. Improvements in the non-alcoholic fatty liver disease activity score and fibrosis stage were examined. In Case 1, pre-treatment liver biopsy revealed 90% steatosis, ballooning, lobular inflammation, and fibrosis (Brunt grade 2, stage 3). Post-treatment, steatosis decreased to 50%, ballooning and inflammation resolved, and fibrosis improved (grade 1, stage 2). In Case 2, pre-treatment liver biopsy showed 70% steatosis, mild lobular inflammation, and fibrosis (grade, 1, stage 3). Post-treatment, steatosis increased to 90%, inflammation resolved, and fibrosis improved (grade 1, stage 1). The fibrosis-4 index improved in both cases; however, shear wave elastography showed no improvement. Pemafibrate may exert antifibrotic and anti-inflammatory effects in MASLD regardless of steatosis trends and that histological assessment remains crucial, especially when non-invasive markers provide inconsistent results. This is the first report to confirm histopathological improvement with pemafibrate via serial liver biopsy, offering important insights into its therapeutic potential for MASLD with dyslipidemia.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"931-937"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic focal nodular hyperplasia after liver transplantation: case report and review of literature. 肝移植术后肝局灶性结节增生1例报告及文献复习。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-18 DOI: 10.1007/s12328-025-02180-5
Kenichi Nakamura, Yoshinori Ozono, Satoru Hasuike, Hiroshi Hatada, Naomi Uchiyama, Yuri Komaki, Hisayoshi Iwakiri, Kenji Nagata, Yoshiko Umekita, Shinichi Aishima, Hiroshi Kawakami

Patients with decompensated cirrhosis complicated by hepatocellular carcinoma (HCC) or those who have undergone liver transplantation following liver failure after HCC treatment should continue to receive post-transplant surveillance. Any new liver tumor must be carefully evaluated to determine whether it is a recurrence of HCC. Focal nodular hyperplasia (FNH), the second most common benign hepatic tumor, is believed to result from the hyperplastic response of hepatocytes to pre-existing vascular malformation. Here, we report a case of hepatic FNH two years after living-donor liver transplantation in a patient who experienced liver failure following treatment for HCC. Given the rarity of hepatic FNH after liver transplantation, we present this case along with a review of the literature.

失代偿性肝硬化合并肝细胞癌(HCC)患者或HCC治疗后肝功能衰竭行肝移植的患者应继续接受移植后监测。任何新的肝肿瘤都必须仔细评估,以确定是否为HCC复发。局灶性结节性增生(FNH)是第二常见的肝脏良性肿瘤,被认为是由肝细胞对原有血管畸形的增生性反应引起的。在这里,我们报告了一例肝移植两年后肝脏FNH的病例,该患者在HCC治疗后出现肝功能衰竭。鉴于肝移植后肝脏FNH的罕见性,我们提出了这个病例,并回顾了文献。
{"title":"Hepatic focal nodular hyperplasia after liver transplantation: case report and review of literature.","authors":"Kenichi Nakamura, Yoshinori Ozono, Satoru Hasuike, Hiroshi Hatada, Naomi Uchiyama, Yuri Komaki, Hisayoshi Iwakiri, Kenji Nagata, Yoshiko Umekita, Shinichi Aishima, Hiroshi Kawakami","doi":"10.1007/s12328-025-02180-5","DOIUrl":"10.1007/s12328-025-02180-5","url":null,"abstract":"<p><p>Patients with decompensated cirrhosis complicated by hepatocellular carcinoma (HCC) or those who have undergone liver transplantation following liver failure after HCC treatment should continue to receive post-transplant surveillance. Any new liver tumor must be carefully evaluated to determine whether it is a recurrence of HCC. Focal nodular hyperplasia (FNH), the second most common benign hepatic tumor, is believed to result from the hyperplastic response of hepatocytes to pre-existing vascular malformation. Here, we report a case of hepatic FNH two years after living-donor liver transplantation in a patient who experienced liver failure following treatment for HCC. Given the rarity of hepatic FNH after liver transplantation, we present this case along with a review of the literature.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"910-917"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paradoxical carbon dioxide embolism through an iatrogenic atrial septal defect after catheter ablation for atrial fibrillation during laparoscopic hepatectomy: two case reports and a brief review of the literature (with video). 腹腔镜肝切除术中房颤导管消融后经由医源性房间隔缺损引起的矛盾二氧化碳栓塞:两例报告和文献简要回顾(附视频)。
IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-10-01 Epub Date: 2025-08-05 DOI: 10.1007/s12328-025-02196-x
Yu Saito, Yuji Morine, Shinichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Mitsuo Shimada

Carbon dioxide (CO2) embolism is an intraoperative complication during laparoscopic hepatectomy (Hx). Paradoxical CO2 embolism with right-to-left systemic shunting can cause cerebral infarction. Iatrogenic atrial septal defect (IASD) can occur after catheter ablation (CA) for atrial fibrillation (AF), and patients with IASD are at risk of paradoxical CO2 embolism. The present case report described two CO2 embolism cases during laparoscopic Hx after CA for Af (one is a paradoxical CO2 embolism). Intraoperative transesophageal echocardiography (TEE) is required for quick identification of CO2 embolism, and the procedure should be converted to laparotomy when paradoxical CO2 embolism occurs. Those patients were fortunately discharged without any postoperative morbidity. CA for AF may increase the risk of paradoxical CO2 embolism. The indication for laparoscopic Hx should be carefully judged based on the surgical procedure and the findings of preoperative TEE. Intraoperative TEE may be beneficial for early detection for quick identification of CO2 embolism, and the procedure should be converted to laparotomy when paradoxical CO2 embolism occurs.

二氧化碳(CO2)栓塞是腹腔镜肝切除术(Hx)的术中并发症。矛盾的CO2栓塞伴右至左全身分流可引起脑梗死。医源性房间隔缺损(IASD)可在房颤(AF)的导管消融(CA)后发生,并且IASD患者存在矛盾性CO2栓塞的风险。本病例报告描述了两例CO2栓塞病例,在腹腔镜Hx手术后,CA为房颤(一个是矛盾的CO2栓塞)。术中需要经食管超声心动图(TEE)快速识别CO2栓塞,当出现异位CO2栓塞时应转为开腹手术。幸运的是,这些患者出院后没有任何术后并发症。房颤合并CA可能增加矛盾型CO2栓塞的风险。腹腔镜Hx的适应症应根据手术方法和术前TEE检查结果仔细判断。术中TEE可能有利于早期发现,快速识别CO2栓塞,当出现异位CO2栓塞时,应改为开腹手术。
{"title":"Paradoxical carbon dioxide embolism through an iatrogenic atrial septal defect after catheter ablation for atrial fibrillation during laparoscopic hepatectomy: two case reports and a brief review of the literature (with video).","authors":"Yu Saito, Yuji Morine, Shinichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Mitsuo Shimada","doi":"10.1007/s12328-025-02196-x","DOIUrl":"10.1007/s12328-025-02196-x","url":null,"abstract":"<p><p>Carbon dioxide (CO<sub>2</sub>) embolism is an intraoperative complication during laparoscopic hepatectomy (Hx). Paradoxical CO<sub>2</sub> embolism with right-to-left systemic shunting can cause cerebral infarction. Iatrogenic atrial septal defect (IASD) can occur after catheter ablation (CA) for atrial fibrillation (AF), and patients with IASD are at risk of paradoxical CO<sub>2</sub> embolism. The present case report described two CO<sub>2</sub> embolism cases during laparoscopic Hx after CA for Af (one is a paradoxical CO<sub>2</sub> embolism). Intraoperative transesophageal echocardiography (TEE) is required for quick identification of CO<sub>2</sub> embolism, and the procedure should be converted to laparotomy when paradoxical CO<sub>2</sub> embolism occurs. Those patients were fortunately discharged without any postoperative morbidity. CA for AF may increase the risk of paradoxical CO<sub>2</sub> embolism. The indication for laparoscopic Hx should be carefully judged based on the surgical procedure and the findings of preoperative TEE. Intraoperative TEE may be beneficial for early detection for quick identification of CO<sub>2</sub> embolism, and the procedure should be converted to laparotomy when paradoxical CO<sub>2</sub> embolism occurs.</p>","PeriodicalId":10364,"journal":{"name":"Clinical Journal of Gastroenterology","volume":" ","pages":"1000-1006"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Journal of Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1